PTH1R Inhibitors
3 drugsAbout PTH1R
The parathyroid hormone 1 receptor (PTH1R) is a GPCR crucial for calcium homeostasis, activated by parathyroid hormone (PTH) and PTHrP. This activation triggers signaling pathways regulating bone remodeling, kidney function, and calcium levels.
PTH1R's established physiological function makes it a valuable drug target, though no genetic evidence directly links it to specific diseases. Therapeutics address conditions where calcium regulation is disrupted.
PTH1R is targeted by two FDA-approved peptide drugs: YORVIPATH and TYMLOS. These drugs are developed by ASCENDIS PHARMA BONE and RADIUS, respectively, for other therapeutic areas.
Top PTH1R Drugs
The PTH1R competitive landscape includes ASCENDIS PHARMA BONE and RADIUS, each with an approved drug.
Low market concentration suggests opportunities for new entrants, but high barriers to entry due to established players.
PTH1R Drug Modality Landscape
Modalities
Routes of Administration
PTH1R is primarily targeted by peptide modalities (67% of approved drugs).
Explore non-peptide modalities to differentiate from existing therapies and expand market reach.
📈 Modality Evolution
other biologics pioneered PTH1R targeting (2015), with peptides entering more recently (2017).
PTH1R Clinical Trials 20 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PTH1R. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 1 | 1 | 0 | 50% |
| Phase 2 | 10 | 6 | 2 | 2 | 75% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
| Phase 4 | 5 | 2 | 2 | 1 | 50% |
Top Sponsors
By Modality
Top Conditions
PTH1R Drug Approval Timeline (2015 - 2024)
The first PTH1R drug was approved in 2017 (TYMLOS), with the most recent approval in 2024 (YORVIPATH).
Recent approval indicates continued interest, but monitor for market saturation as the field matures.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 14 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PTH1R. A trial counts if an approved drug acting on PTH1R is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.